2 studies found for:    22992073 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Condition: Multiple Sclerosis
Interventions: Drug: Rebif (IFN β-1a subcutaneous three times per week);   Drug: Tecifdera (dimethyl fumarate)
2 Completed
Has Results
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BG00012;   Drug: Placebo

Indicates status has not been verified in more than two years